Tobramycin: efficacy of intensive therapy
Keywords:aminoglycosides, tobramycin, Pseudomonas aeruginosa
One of the leading cause of the decrease of treatment efficacy in patient with community-acquired infections in the intensive care department is a spread of antibiotic resistance in main causative agents. Among Gram-negative microorganisms Pseudomonas aeruginosa is one of the leading causative agents, that is related to health service. A review of foreign and domestic literature concerning tobramycin – systemic form use in the current medical practice in the conditions of increasing resistance of microorganisms to the most broad-spectrum antibiotics is presented in the article. Pharmacokinetic and pharmacodynamic characteristics of tobramycin are described, results of clinical trials, that demonstrate an efficacy of its use in the combination with other antibiotics in the life-threatening infections caused by Gram-negative microorganisms are presented in the article.
Strich JR, Kadri SS. Difficult-to-Treat Antibiotic-Resistant Gram-negative Pathogens in the Intensive Care Unit: Epide-miology, Outcomes, and Treatment. Seminars in Respirato-ry and Critical Care Medicine [Internet]. Georg Thieme Verlag KG; 2019 Aug;40(04):419–34. Available from: https://doi.org/10.1055/s-0039–1696662
Haijia Lu, Dongfeng Zhang, and Haihong Huang. “Research Prog-ress on Anti-Gram-negative Bacteria Drugs.” Acta Pharmaceutical Sciences. 2019; 54.9: 1554–1563.
Burnham JP, Olsen MA, Kollef MH. Re-estimating annual deaths due to multidrug-resistant organism infections. Infection Control & Hospital Epidemiology [Internet]. Cambridge University Press (CUP); 2018 nov 22;40(1):112–3. Available from: https://doi.org/10.1017/ice.2018.304
Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, et al. Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents. Clinical Infectious Diseases [Internet]. Oxford University Press (OUP); 2018 Jul 23; Available from: https://doi.org/10.1093/cid/ciy378
national Center for Biotechnology Information (2020). PubChem Compound Summary for CID 36294, Tobramycin. Retrieved Au-gust 13, 2020 from https://pubchem.ncbi.nlm.nih.gov/compound/Tobramycin.
Winnicka K, Wroblewska M, Wieczorek P, Sacha P, Tryniszewska E. The Effect of PAMAM Dendrimers on the Antibacterial Activity of Antibiotics with Different Water Solubility. Molecules [Internet]. MDPI AG; 2013 Jul 22;18(7):8607–17. Available from: https://doi.org/10.3390/molecules18078607
Golub AV. “The place of tobramycin in modern clinical practice.” Clinical Microbiology and Antimicrobial Chemotherapy 12.4 (2010)
Domalaon R, Ammeter D, Brizuela M, Gorityala BK, Zhanel GG, Schweizer F. Repurposed Antimicrobial Combination Therapy: Tobramycin-Ciprofloxacin Hybrid Augments Activity of the Anti-cancer Drug Mitomycin C Against Multidrug-Resistant Gram-neg-ative Bacteria. Frontiers in Microbiology [Internet]. Frontiers Me-dia SA; 2019 Jul 10;10. Available from: https://doi.org/10.3389/fmicb.2019.01556
Swaraj, Bighneswar Baliyarsingh, and Suraja Kumar nayak. “Anti-microbial Resistance in Pseudomonas aeruginosa: A Concise Review.” Antimicrobial Resistance. IntechOpen, 2020
Tunkel AR, Hasbun R, Bhimraj A, Byers K, Kaplan SL, Scheld WM, et al. 2017 Infectious Diseases Society of America’s Clinical Prac-tice Guidelines for Healthcare-Associated Ventriculitis and Men-ingitis*. Clinical Infectious Diseases [Internet]. Oxford University Press (OUP); 2017 Feb 14;64(6):e34â€“e65. Available from: https://doi.org/10.1093/cid/ciw861
Vazquez Espinosa E, Giron Moreno RM, Gomez Punter RM, Garcia Castillo E, Valenzuela C, Cisneros Serrano C, et al. Long-term safe-ty and efficacy of tobramycin in the management of cystic fibrosis. Therapeutics and Clinical Risk Management [Internet]. Informa UK Limited; 2015 Mar;407. Available from: https://doi.org/10.2147/tcrm.s75208
Reyhanoglu, Gizem, and Anil Kumar Reddy Reddivari. “Tobramy-cin.” StatPearls [Internet]. StatPearls Publishing. 2019.
Louisa, et al. “Outpatient parenteral antimicrobial therapy: a report of three years experience.” (2014)
Marie J-P, Marjanovic Z, Vekhoff A, Bouvet A, Chast F, Levy V, et al. Piperacillin/tazobactam plus tobramycin versus ceftazidime plus tobramycin as empiric therapy for fever in severely neutropenic patients. Supportive Care in Cancer [Internet]. Springer Science and Business Media LLC; 1999 Feb 8;7(2):89–94. Available from: https://doi.org/10.1007/s005200050233
May AK. An Argument for the Use of Aminoglycosides in the Em-piric Treatment of Ventilator-Associated Pneumonia. Surgical In-fections [Internet]. Mary Ann Liebert Inc; 2016 Jun;17(3):329–33. Available from: https://doi.org/10.1089/sur.2015.276
Klingel M, Stanojevic S, Tullis E, Ratjen F, Waters V. Oral Azith-romycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis. Annals of the American Thoracic Society [Internet]. American Thorac-ic Society; 2019 Jul;16(7):861–7. Available from: https://doi.org/10.1513/annalsats.201811–774oc
Abid, et al. “Microbial profile of burn wound infections and their antibiotic sensitivity patterns at burn unit of allied hospital Faisal-abad.” Pakistan journal of pharmaceutical sciences 32 (2019)
Dmitriev DV, nazarchuk OA, Babina UM, Maistruk SB. Clinical and microbiological study of the effectiveness of aminoglycosides in purulent-inflammatory processes. Annals of Mechnikov Institute. 2020; 2: 77–85. DOI: 10.5281/zenodo.3885199
Xuan D. Population pharmacokinetics of tobramycin in hospital-ized patients receiving once-daily dosing regimen. Internation-al Journal of Antimicrobial Agents [Internet]. Elsevier BV; 2000 Jul;15(3):185–91. Available from: https://doi.org/10.1016/s0924–8579(00)00172–2
Viktorov OP, et al. “Side effects of aminoglycoside antibiotics: gen-tamicin.” Today problems Toxicology; 3(2002):72–76.
Deschamp AR, Pettit RS, Donaldson JA, Slaven JE, Davis SD. Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fi-brosis. SAGE Open Medicine [Internet]. SAGE Publications; 2017 Oct 16;5:205031211773669. Available from: https://doi.org/10.1177/2050312117736694
How to Cite
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International License